Chemotherapy and the Treatment of Brain Metastases

Hematology/Oncology Clinics of North America

Volumn 20, Issue 6, 2006, Pages 1287-1295

  Peak, Scott ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CAPECITABINE; EFAPROXIRAL; GADOLINIUM TEXAPHYRIN; GEFITINIB; GLYCOPROTEIN P; METHOTREXATE; MONOCLONAL ANTIBODY; OXYGEN; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; THALIDOMIDE; VALSPODAR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BIOLOGY; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; BRAIN TISSUE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPOXEMIA; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOSENSITIZATION; RADIOSURGERY; REVIEW; SYSTEMIC DISEASE;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS;

EID: 33750946984     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.09.007     Document Type: Review

References (33)

1. Nathoo N., Chahlavi A., Barnett G.H., et al. Pathobiology of brain metastases. J Clin Pathol 58 (2005) 237-242
2. Posner J.B. Pathophysiology of metastases to the nervous system. In: Posner J.B. (Ed). Neurologic complications of cancer (1995), F. A. Davis, Philadelphia 15-35
3. Steeg P.S., Ouatas T., Halverson D., et al. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 4 1 (2003) 51-62
4. Weil R.J., Palmieri D.C., Bronder J.L., et al. Breast cancer metastasis to the central nervous system. Am J Pathol 167 4 (2005) 913-920
5. Fidler I.J., Schackert G., Zhang R., et al. The biology of melanoma brain metastasis. Cancer Metastasis Rev 18 (1999) 387-400
6. Steeg P.S. Emissaries set up new sites. Nature 438 8 (2005) 750-751
7. Kaplan R.N., Riba R., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 8 (2005) 820-827
8. Yano S., Shinohara H., Herbst R.S., et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60 (2000) 4959-4967
9. Kristensen C.A., Kristjansen P.E., and Hansen H.H. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10 (1992) 1498-1502
10. van den Bent M.J. The role of chemotherapy in brain metastases. Eur J Cancer 39 (2003) 2114-2120
11. Postmus P.E., and Smit E.F. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 10 (1999) 753-759
12. Evens A.M. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 16 6 (2004) 576-580
13. Suh J.H., Stea B., Nabid A., et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24 1 (2006) 106-114
14. Antonadou D., Paraskevaidis M., Sarris G., et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20 17 (2002) 3644-3650
15. Verger E., Gil M., Yaya R., et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61 1 (2005) 185-191
16. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
17. Carde P., Timmerman R., Mehta M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19 7 (2001) 2074-2083
18. Mehta M.P., Shapiro W.R., Glantz M.J., et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20 16 (2002) 3445-3453
19. Mehta M.P., Rodrigus P., Terhaard C.H.J., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 13 (2003) 2529-2536
20. Mehta M.P., and Khuntia D. Current strategies in whole-brain radiation therapy for brain metastases. Neurosurgery 57 5 (2005) 5433-5444
21. Hofmann M., Kiecker F., Wurm R., et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 76 (2006) 59-64
22. Abrey L.E., Olson J.D., Raizer J.J., et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53 (2001) 259-265
23. Agarwala S.S., Kirkwood J.M., Gore M., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22 11 (2004) 2101-2107
24. Wen-Jen H., Lis E., Menell J.H., et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103 12 (2005) 2590-2597
25. Lassman A.B., Abrey L.E., Shah G., et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 13 (2006) 1-6
26. Tetef M.L., Margolin K.A., Doroshow J.H., et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46 1 (2000) 19-26
27. Siegelmann-Danieli N., Stein M., and Jacob B.Z. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 5 (2003) 833-834
28. Hikino H., Yamada T., Johbara K., et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 15 1 (2006) 97-99
29. Wang M.L., Yung W.K., Royce M.E., et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24 4 (2001) 421-424
30. Choong N.W., Dietrich S., Seiwert T.Y., et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 3 1 (2006) 50-57
31. Namba Y., Kijima T., Yokota S., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6 2 (2004) 123-128
32. Ceresoli G.L., Cappuzzo F., Gregorc V., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15 (2004) 1042-1047
33. Doolittle N.D., Abrey L.E., Bleyer W.A., et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual blood-brain barrier disruption consortium meeting. Clin Can Res 11 (2005) 421-428